Zoetis revenue
Zoetis's revenue was $9.47bn in fiscal 2025, up 2.3% on the year before. Since fiscal 2011 ($4.23bn) it has grown at a compound 5.9% a year. Over the last twelve months it was $9.52bn.
Revenue history
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,233 | 4,336 | 4,561 | 4,785 | 4,765 | 4,888 | 5,307 | 5,825 | 6,260 | 6,675 | 7,776 | 8,080 | 8,544 | 9,256 | 9,467 | 9,517 |
| Growth on the year before | — | +2.4% | +5.2% | +4.9% | −0.4% | +2.6% | +8.6% | +9.8% | +7.5% | +6.6% | +16.5% | +3.9% | +5.7% | +8.3% | +2.3% | — |
| Gross profit | 2,581 | 2,773 | 2,892 | 3,068 | 3,027 | 3,222 | 3,532 | 3,914 | 4,268 | 4,618 | 5,473 | 5,626 | 5,983 | 6,537 | 6,801 | 6,808 |
| Gross margin | 61.0% | 64.0% | 63.4% | 64.1% | 63.5% | 65.9% | 66.6% | 67.2% | 68.2% | 69.2% | 70.4% | 69.6% | 70.0% | 70.6% | 71.8% | 71.5% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Total Products and Services | $9.4B | ▲ 1.9% |
| Companion Animal | $6.6B | ▲ 4.9% |
| Horses | $6.3B | ▲ 4.8% |
| Livestock | $2.8B | ▼ 4.6% |
| Parasiticides | $2.3B | ▲ 8.7% |
| Vaccines | $2B | ▲ 7.2% |
| Dermatology | $1.8B | ▲ 6.0% |
| Cattle | $1.5B | ▼ 2.5% |
| Anti Infective Products | $1B | ▼ 5.8% |
| Pain Sedation | $840M | ▼ 1.3% |
| Other Pharmaceuticals | $697M | ▲ 5.9% |
| Swine | $466M | ▼ 9.7% |
| Animal Health Diagnostics | $434M | ▲ 12.4% |
| Poultry | $432M | ▼ 18.0% |
| Dogs and Cats | $304M | ▲ 6.7% |
| Fish | $286M | ▲ 18.2% |
| Other Non Pharmaceuticals | $263M | ▲ 4.0% |
| Contract Manufacturing and Human Health Diagnostics | $116M | ▲ 45.0% |
| Manufactured Product Other | $88M | ▲ 7.3% |
| Medicated Feed Additives | $27M | ▼ 90.8% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | YoY |
|---|---|---|
| Total Geographical Area | $9.4B | ▲ 1.9% |
| United States | $5.1B | ▲ 0.5% |
| Other Emerging Markets | $913M | ▲ 5.5% |
| Other Developed Markets | $641M | ▲ 13.7% |
| Brazil | $393M | ▼ 5.1% |
| Australia | $329M | ▲ 3.1% |
| United Kingdom | $325M | ▲ 3.5% |
| Canada | $290M | ▲ 4.7% |
| Germany | $236M | ▲ 4.9% |
| China | $227M | ▼ 15.9% |
| France | $165M | ▲ 5.8% |
| Mexico | $160M | ▼ 5.3% |
| Japan | $154M | ▲ 4.8% |
| ES | $145M | ▲ 11.5% |
| CL | $139M | ▲ 13.0% |
| IT | $137M | ▲ 6.2% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Zoetis's 10-K filed February 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Zoetis | $9.52bn | 1.5% | 5.0% |
| Bausch Health Companies Inc. | $11.11bn | 10.8% | 9.2% |
| Haleon plc | $14.55bn | 1.3% | — |
| Viatris | $14.74bn | 4.4% | -1.9% |
| Organon & Co. | $6.10bn | -3.2% | -0.3% |
| Universe Pharmaceuticals Inc | $17.86bn | -22.4% | — |
Compare with peers
- Bausch Health Companies Inc. revenue
- Haleon plc revenue
- Viatris revenue
- Organon & Co. revenue
- Universe Pharmaceuticals Inc revenue
Head to head: BHC vs ZTSHLN vs ZTSVTRS vs ZTSOGN vs ZTS
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies